Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer, Lilly And Merck Strike Up Cancer Research Partnership In Asia

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly, Pfizer and Merck - like many Big Pharma - are hoping to spur growth in the future by addressing unmet medical need in Asia's emerging markets. The three companies hope to accelerate research in addressing Asia's most-commonly diagnosed cancers with a non-competitive collaboration - perhaps the first of its kind in the region - to share data for the next several years
Advertisement

Related Content

Pfizer Senior VP And Head Of Worldwide PharmaTherapeutics Research Rod MacKenzie On Moving R&D To China: An Interview With PharmAsia News (Part 2 of 2)
Translational R&D Models Like Precompetitive Alliances Needed To Energize Drug Discovery - Indian Symposium
Piramal Life Sciences CEO Somesh Sharma On Managing Risk And India's Potential For Discovering New Drugs: An Interview With PharmAsia News (Part 2 of 2)
Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way
Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way
Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says
Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says
With Spotlight On China, Regional Asian Opportunities Are Also Bright
Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference
Big Pharma Stretches To Reshape Itself To Enter Asia With Flexible, Multiple-Partner Networks – Singapore Conference
Advertisement
UsernamePublicRestriction

Register

SC074124

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel